These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36263004)

  • 1. Prognostic Signature GXYLT2 Is Correlated with Immune Infiltration in Bladder Cancer.
    Wu S; Qiu S; Chen W; Ding L; Wu L
    Dis Markers; 2022; 2022():5081413. PubMed ID: 36263004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
    Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
    Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucoside xylosyltransferase 2 as a diagnostic and prognostic marker in gastric cancer via comprehensive analysis.
    Zhao Y; Hu S; Zhang J; Cai Z; Wang S; Liu M; Dai J; Gao Y
    Bioengineered; 2021 Dec; 12(1):5641-5654. PubMed ID: 34506251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of
    Lin B; Zhang T; Ye X; Yang H
    Oncol Lett; 2020 Sep; 20(3):2840-2854. PubMed ID: 32782602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
    Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of SNCA and its methylation in bladder cancer.
    Wu Z; Xia C; Zhang C; Yang D; Ma K
    BMC Cancer; 2022 Mar; 22(1):330. PubMed ID: 35346107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
    Sun S; Wang Y; Wang J; Bi J
    J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    Chen F; Wang Q; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2 Family Members in Bladder Cancer from Database and FFPE Sample.
    Yuan F; Sun Y; Dai GC; Yao Q; Zhou YB; Zang YC; Liu XL; Xue BX
    J Cancer; 2023; 14(16):3050-3065. PubMed ID: 37859819
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA.
    Ding Y; Liu N; Chen M; Xu Y; Fang S; Xiang W; Hua X; Chen G; Zhong Y; Yu H
    World J Surg Oncol; 2021 Apr; 19(1):133. PubMed ID: 33888142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
    Sun X; Chen Q; Zhang L; Chen J; Zhang X
    Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.